ReviewOpen veterinary journal2025
Therapeutic effects of single-clove garlic extract on nicotine-induced inflammation and histopathological changes in rats.
Review in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of Nicotine administration on α7nAChR, miR-124, STAT3, and inflammatory markers in Rat Lung Tissue.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nicotine exposure causes cellular damage by generating reactive oxygen species, leading to inflammation. DNA damage, and diseases such as atherosclerosis. Single-clove garlic extract (SCGE) contains antioxidants such as allicin and flavonoids that may counteract nicotine's harmful effects by reducing pro-inflammatory cytokines, suggesting SCGE's potential as a natural therapeutic intervention to support good health. Aim: This study aimed to investigate the effects of SCGE against nicotine-induced pneumotoxicity in rats by assessing its impact on TNF-α, interleukin 6 (IL-6), and structural integrity tracheal, pulmonary, and coronary artery tissues. Methods: The subjects of this study were 30 male rats which were divided into the following 5 treatment groups: T1 (negative control), T2 (3 mg/ml of nicotine), and T3 (3 mg/ml of nicotine and 3.6 mg/day vitamin C), T4; T5; T6 groups (3 mg/ml nicotine and 75; 100; 125 kg/mg body weight of SCGE). A nicotine exposure followed by oral SCGE was administered twice a day consecutively for 14 days. The TNF-α and IL-6 expression was evaluated using immunohistochemical staining. Histopathology of the tracheal and pulmonary organs and coronary arteries was performed using H&E staining. Results: The T4, T5, and T6 groups revealed that TNF-α and IL-6 levels were significantly lower than in T2 (2.90 and 4.72), reducing ciliary damage, epithelial height, and mucosal thickness. The T6 group exhibited significant differences in the coronary arteries (14.97 µm) compared with the T2 (121.36 µm). The mean lumen diameter of the coronary artery of the T4, T5, and T6 groups was increased compared with T2 (49.71 µm). Significant decreases (42,65%) were observed in hemorrhage, alveolar septal thickening, and inflammatory cell infiltration in the T6 compared to T2. Conclusion: In conclusion, SCGE treatment can potentially mitigate pneumotoxicity caused by nicotine, as evidenced by improvements in TNF-α, IL-6, and histopathological damage of the tracheal, pulmonary, and coronary arteries. These findings suggest that SCGE could be explored as a potential natural therapeutic intervention for preventing or treating nicotine-induced lung damage. These findings suggest that SCGE could be explored as a potential natural therapeutic intervention to prevent or treat nicotine-induced lung damage. Further studies could explore the mechanisms underlying SCGE's anti-inflammatory and antioxidant properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.